Randomized Diagnostic Trial Comparing Ethylglucuronide and Ethanol
NCT03276520 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 162
Last updated 2017-09-11
Summary
Background: Alcohol use disorders represent a major health burden. Efforts aiming at reducing alcohol-related harm include early detection of those with risky drinking habits as well detection of early relapse in patients with alcohol dependence who are detoxified and committed to abstinence. Recently, ethyl glucuronide has been proved to be a good biomarker for the detection of recent drinking. However, to date, no randomized diagnostic trial has tested its impact on drinking outcomes. The aim of this study was to assess, with a randomized design, the implications of ethyl glucuronide screening on alcohol outcomes, compared to screening with a low-sensitivity biomarker such as ethanol.
Methods: alcohol dependent outpatients were randomized to either 24 weeks of continuous screening with ethyl glucuronide or ethanol. Patients were aware of screening methods and results. After 24 weeks, all participants were screened with ethyl glucuronide. Self-reports were also gathered. A logistic regression model was performed comparing the rate of ethyl glucuronide positive results at study end between groups. Generalized estimating equations were performed to evaluate the descending rate of EtG positive patients in the EtG group, measured month to month.
Conditions
Interventions
- DIAGNOSTIC_TEST
-
ethyl glucuronide
alcohol urine screening with ethyl glucuronide
- DIAGNOSTIC_TEST
-
ethanol
alcohol urine screening with ethanol
Sponsors & Collaborators
-
Hospital Clinic of Barcelona
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SCREENING
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-12-14
- Primary Completion
- 2017-07-01
- Completion
- 2017-07-31
More Related Trials
-
Oxytocin Treatment of Alcohol Dependence
NCT02275611 ·Status: COMPLETED ·Phase: PHASE2
-
An Open Label Trial of Bupropion and Naltrexone for Binge Drinking
NCT02842073 ·Status: COMPLETED ·Phase: PHASE2
-
Multimodal Neuroimaging of Stress and Reward Cues to Assess Alcoholism Risk and Relapse
NCT02616094 ·Status: COMPLETED ·Phase: NA
-
A Novel Human Lab Model for Screening AUD Medications
NCT04249882 ·Status: COMPLETED ·Phase: PHASE2
-
Exploring Regulation and Function of Dopamine D3 Receptors in Alcohol Use Disorders: A [11C]-(+)-PHNO Study
NCT03037060 ·Status: COMPLETED ·Phase: NA
-
The Role of Neuroactive Steroids in Stress, Alcohol Craving and Alcohol Use in Alcohol Use Disorders
NCT03872128 ·Status: COMPLETED ·Phase: PHASE1
-
Development of a Selective ALDH2 Inhibitor to Treat AUD
NCT04311294 ·Status: WITHDRAWN ·Phase: PHASE2
-
Effect of Endotoxin on Alcohol Consumption
NCT04527185 ·Status: COMPLETED ·Phase: PHASE2
-
Intranasal Oxytocin for the Treatment of Alcohol Use Disorder
NCT03878316 ·Status: COMPLETED ·Phase: PHASE2
-
Ketone Ester Intervention in Alcohol Use Disorder
NCT04616781 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Screening Evaluation for Studies of the National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NCT00001673 ·Status: COMPLETED
-
Sex Differences in the Response to Abstinence From Alcohol.
NCT03827460 ·Status: RECRUITING ·Phase: PHASE1
-
Multimodal Neuroimaging of Alcohol Cues, Cortisol Response, and Compulsive Motivation
NCT04412824 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Individual Variations of Taste and Smell Perception in Alcohol Use Disorder (AUD)
NCT05677321 ·Status: RECRUITING
-
Impulsivity Domains and Subjective Response
NCT05929677 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Relationship Between Brain and Heart Glucose Metabolism in Alcohol Use Disorder
NCT05015881 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2/PHASE3
-
Mental Imagery Intervention for Alcohol Craving
NCT04958655 ·Status: COMPLETED ·Phase: NA
-
PT150 Drug for Use in Alcohol Use Disorder
NCT06712602 ·Status: RECRUITING ·Phase: PHASE1
-
The Role of Brief Potent Glutamatergic Modulation in Addressing Problem Drinking
NCT04084860 ·Status: RECRUITING ·Phase: PHASE2
-
Promoting Medications for Alcohol Use Disorder on the General Medicine Service
NCT04287790 ·Status: TERMINATED
-
Predicting Dropout and Outcome From Neuropsychological Functions in SUD Patients
NCT03220373 ·Status: ACTIVE_NOT_RECRUITING
-
Effectiveness of Naltrexone and/or Ondansetron to Reduce Craving for Alcohol and Drinking
NCT00183222 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Intervention in Alcohol Use Disorder
NCT02168400 ·Status: COMPLETED ·Phase: NA
-
Pilot Evaluation of the Empower Neuromodulation System in AUD Patients
NCT03983317 ·Status: COMPLETED ·Phase: NA
-
Laboratory Studies on Oxytocin for Treatment of Alcohol Use Disorder
NCT02407340 ·Status: COMPLETED ·Phase: PHASE1